Immuno-oncology continues to attract attention and investment for its potential to cure cancer.

While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up?

Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is full of potential successors born from T-Cell Receptors (TCR), monoclonal antibodies (mAbs), T-Cell Fragments, Chimeric Antigen Receptor-modified T cells (CAR-T) and tumor-infiltrating lymphocytes (TIL).

Leer más

Please follow and like us: